Kentera (previously Oxybutynin Nicobrand) Europska Unija - hrvatski - EMA (European Medicines Agency)

kentera (previously oxybutynin nicobrand)

teva b.v.  - oksibutinin - urinarnu inkontinenciju, žuriti - urologicals - simptomatsko liječenje urgentne inkontinencije i / ili povećanu učestalost i hitnost urina kao što se može pojaviti kod odraslih bolesnika s nestabilnim mjehura.

Driptane 5 mg tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

driptane 5 mg tablete

mylan hrvatska d.o.o., koranska 2, zagreb, hrvatska - oksibutininklorid - tableta - 5 mg - urbroj: jedna tableta sadrži 5 mg oksibutininklorida

NEOPENOTRAN Forte 750 mg/1 vagitorija+ 200 mg/1 vagitorija vagitorija Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

neopenotran forte 750 mg/1 vagitorija+ 200 mg/1 vagitorija vagitorija

medis international d.o.o. sarajevo - metronidazol, Миконазол - vagitorija - 750 mg/1 vagitorija+ 200 mg/1 vagitorija - 1 vagitorija sadrži: 750 mg metronidazola i 200 mg mikonazol nitrata

Emselex Europska Unija - hrvatski - EMA (European Medicines Agency)

emselex

pharmaand gmbh - darifenacin hidrobromid - urinary incontinence, urge; urinary bladder, overactive - urologicals, lijekovi za mokrenje i inkontinencija - simptomatsko liječenje urgentne inkontinencije i / ili povećana učestalost i hitnost urina kao što se može pojaviti kod odraslih bolesnika s sindromom prekomjerne aktivnosti mokraćnog mjehura.

Imbruvica Europska Unija - hrvatski - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.